# Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 Days

> **NCT02547805** · PHASE2 · COMPLETED · sponsor: **Allena Pharmaceuticals** · enrollment: 66 (actual)

## Conditions studied

- Secondary Hyperoxaluria
- Nephrolithiasis
- Hyperoxaluria
- Kidney Stones
- Dietary Hyperoxaluria

## Interventions

- **DRUG:** ALLN-177
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02547805
- **Lead sponsor:** Allena Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2017-01
- **Final completion:** 2017-01
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2017-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02547805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02547805, "Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 Days". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02547805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*